Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BSGM NYSE:ELMD NASDAQ:MBOT NASDAQ:NEPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSGMBiosig Technologies$4.78-2.8%$5.81$0.23▼$14.11$150.18M1.65834,087 shs377,575 shsELMDElectromed$24.73+0.8%$19.89$15.06▼$35.56$206.48M0.3884,013 shs79,825 shsMBOTMicrobot Medical$3.81-4.8%$2.87$0.82▼$4.62$173.53M1.153.06 million shs2.50 million shsNEPHNephros$3.73-7.4%$3.82$1.36▼$5.00$39.54M1.1154,285 shs43,100 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSGMBiosig Technologies0.00%-7.72%+3.46%-10.32%+1,095.00%ELMDElectromed0.00%+22.00%+35.80%+22.43%+63.13%MBOTMicrobot Medical0.00%-1.04%+50.59%+47.67%+302.24%NEPHNephros0.00%-10.77%+5.07%+41.83%+101.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSGMBiosig Technologies2.2382 of 5 stars3.50.00.00.02.21.70.6ELMDElectromed3.1658 of 5 stars3.73.00.00.02.61.71.3MBOTMicrobot Medical1.3307 of 5 stars3.31.00.00.02.20.00.6NEPHNephros3.0018 of 5 stars3.53.00.00.03.30.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSGMBiosig Technologies 3.00Buy$10.00109.21% UpsideELMDElectromed 3.33Buy$36.2546.58% UpsideMBOTMicrobot Medical 2.50Moderate Buy$9.00136.22% UpsideNEPHNephros 3.00Buy$5.5047.45% UpsideCurrent Analyst Ratings BreakdownLatest NEPH, MBOT, ELMD, and BSGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025ELMDElectromedLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$36.008/27/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $35.008/27/2025ELMDElectromedLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.008/21/2025MBOTMicrobot MedicalZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/8/2025NEPHNephrosMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $6.007/22/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$29.007/21/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/6/2025BSGMBiosig TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.50 ➝ $10.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSGMBiosig Technologies$40K3,754.69N/AN/A($0.11) per share-43.45ELMDElectromed$64M3.23$0.60 per share41.36$5.10 per share4.85MBOTMicrobot MedicalN/AN/AN/AN/A$0.67 per shareN/ANEPHNephros$14.16M2.79$0.02 per share186.40$0.91 per share4.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSGMBiosig Technologies-$10.33MN/A0.00N/AN/AN/A-5,336.99%-90.03%11/13/2025 (Estimated)ELMDElectromed$5.15M$0.8432.97∞N/A11.34%15.71%13.37%N/AMBOTMicrobot Medical-$11.44M-$0.58N/AN/AN/AN/A-76.27%-67.54%11/12/2025 (Estimated)NEPHNephros$70K$0.1231.08∞N/A7.95%14.89%11.64%11/6/2025 (Estimated)Latest NEPH, MBOT, ELMD, and BSGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025BSGMBiosig Technologies-$0.04-$0.74-$0.70-$0.74N/AN/A8/12/2025Q2 2025MBOTMicrobot Medical-$0.08-$0.10-$0.02-$0.10$1.00 millionN/A8/7/2025Q2 2025NEPHNephros-$0.0250$0.02+$0.0450$0.02$3.60 million$4.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSGMBiosig TechnologiesN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSGMBiosig TechnologiesN/A0.030.03ELMDElectromedN/A5.104.74MBOTMicrobot MedicalN/A12.0612.06NEPHNephrosN/A5.414.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSGMBiosig Technologies7.16%ELMDElectromed40.82%MBOTMicrobot Medical16.30%NEPHNephros41.10%Insider OwnershipCompanyInsider OwnershipBSGMBiosig Technologies24.80%ELMDElectromed14.00%MBOTMicrobot Medical4.74%NEPHNephros6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSGMBiosig Technologies5031.42 million23.63 millionNo DataELMDElectromed1608.35 million7.36 millionOptionableMBOTMicrobot Medical2045.55 million43.39 millionOptionableNEPHNephros3010.60 million9.89 millionNot OptionableNEPH, MBOT, ELMD, and BSGM HeadlinesRecent News About These CompaniesNephros (NASDAQ:NEPH) Shares Down 7.4% - What's Next?August 30 at 3:13 AM | americanbankingnews.comNephros Second Quarter 2025 Earnings: Beats ExpectationsAugust 10, 2025 | finance.yahoo.comNephros Inc (NEPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Profitability ...August 9, 2025 | finance.yahoo.com�Nephros Announces Strong Second Quarter Financial ResultsAugust 7, 2025 | prismmediawire.comPNephros Announces Strong Second Quarter Financial ResultsAugust 7, 2025 | globenewswire.com�Nephros Schedules Second Quarter 2025 Financial Results Conference CallJuly 31, 2025 | prismmediawire.comPNephros Schedules Second Quarter 2025 Financial Results Conference CallJuly 31, 2025 | globenewswire.comNephros Inc. (NEPH) Stock Price Today - WSJJuly 4, 2025 | wsj.comJune 2025's Promising Penny Stocks With Growth PotentialJune 23, 2025 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Shares Could Be 37% Below Their Intrinsic Value EstimateJune 23, 2025 | uk.finance.yahoo.comNephros to Host Analyst and Investor Virtual EventMay 30, 2025 | finance.yahoo.comNephros First Quarter 2025 Earnings: Beats ExpectationsMay 10, 2025 | finance.yahoo.comNephros’s new microfilter offers enhanced installation flexibility for bacterial retentionApril 30, 2025 | filtsep.comFNephros Schedules First Quarter 2025 Financial Results Conference CallApril 30, 2025 | finance.yahoo.comNephros expands filtration line with new S100 In-Line filterApril 29, 2025 | investing.comNephros Launches New S100 In-Line MicrofilterApril 28, 2025 | finance.yahoo.comNephros Full Year 2024 Earnings: Beats ExpectationsMarch 28, 2025 | finance.yahoo.comEQS-News: Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 8, 2025 | markets.businessinsider.comNephros Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 7, 2025 | theglobeandmail.comNephros Amends CFO Employment Terms for Strategic GrowthMarch 4, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025NEPH, MBOT, ELMD, and BSGM Company DescriptionsBiosig Technologies NASDAQ:BSGM$4.78 -0.14 (-2.85%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.88 +0.11 (+2.20%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.Electromed NYSE:ELMD$24.73 +0.20 (+0.82%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$24.70 -0.03 (-0.12%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Microbot Medical NASDAQ:MBOT$3.81 -0.19 (-4.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.88 +0.07 (+1.84%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Nephros NASDAQ:NEPH$3.73 -0.30 (-7.44%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.72 0.00 (-0.13%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
